ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
Tanaka K, Kandori S, Sakka S, Nitta S, Tanuma K, Shiga M, Nagumo Y, Negoro H, Kojima T, Mathis BJ, Shimazui T, Watanabe M, Sato TA, Miyamoto T, Matsuzaka T, Shimano H, Nishiyama H.
Tanaka K, et al. Among authors: mathis bj.
Oncol Rep. 2022 Feb;47(2):23. doi: 10.3892/or.2021.8234. Epub 2021 Nov 29.
Oncol Rep. 2022.
PMID: 34841437
Free PMC article.